

Pearce IP

Intellectual property specialists for the pharmaceutical and biopharmaceutical industries.
Providing IP services from early R&D to commercial launch, and beyond.
At Pearce IP, our lawyers want to change the world. We work with life sciences organisations, creating and implementing Intellectual Property strategies supporting the timely development and launch of medicines. We help change the world, one patent at a time.

Legal Influencer

Pearce IP

CONNECT WITH US

in

Filter by Jurisdiction

Filter by work area

Articles

Events

Press Releases

Most Popular

Australia. Preliminary Discovery. A New Frontier... Using PD to Build a Validity Challenge

Pearce IP, Australia , 28 Aug 26

Alvotech & Lotus Enter Licensing Agreement for Durvalumab and Emicizumab Biosimilars in the US and 8 Asian Markets

Pearce IP, Asia-Pacific, USA , 21 Aug 26

Celltrion Launches Biosimilar Ustekinumab IV Formulation in Japan

Pearce IP, Japan , 21 Aug 26

PBAC Recommends Reimbursement for Ustekinumab & Aflibercept Biosimilars

Pearce IP, Australia , 21 Aug 26

Pearce IP BioBlast® for the week ending 21 August 2026

Pearce IP, Australia, European Union, Japan... , 25 Aug 26

Sam Chun Dang Settles Aflibercept Disputes with Regeneron & Bayer in Europe, Japan and South Korea

Pearce IP, European Union, Japan, South Korea , 18 Aug 26

Positive Results for Chia Tai Tianqing's Biosimilar Pertuzumab Ph 3 Trials

Pearce IP, China , 26 Aug 26

Celltrion Files Second Korean Application for Biosimilar to MSD's Keytruda® (Pembrolizumab)

Pearce IP, South Korea , 24 Aug 26

War and Peace (But Mostly War)... Inside Australia's Longest-Running Industrial Chemistry Feud

Pearce IP, Australia , 28 Aug 26

Pearce IP BioBlast® for the week ending 28 August 2026

Pearce IP, Australia, China, European Union... , 01 Sep 26

FDA Approves Biocon's Biosimilar Ustekinumab Autoinjector

Pearce IP, USA , 18 Aug 26

Bio-Thera & Avalon Partner on Biosimilar to Sanofi/Regeneron's Dupixent® (Dupilumab) in MENA

Pearce IP, Africa, Middle East , 18 Aug 26

More

Author Leaderboard

Show:

7 days

30 days

90 days

1.

Helen Macpherson

Pearce IP

2.

Naomi Pearce

Pearce IP

3.

Paul Johns

Pearce IP

4.

Pearce IP Authors

5.

Pearce IP Authors

Lexology Legal Influencers

Lexology's Legal Influencers programme recognises firms and authors that provide excellent content within a work area and region. [Find out more.](#)

Legal Influencer: Pearce IP

Q1 2026 in Dispute resolution - Australasia
Q1 2026 in Healthcare and life sciences - Australasia
Q1 2026 in Healthcare and life sciences - Cross-border
Q4 2025 in Dispute resolution - Australasia
Q4 2025 in Healthcare and life sciences - Australasia
Q4 2025 in Healthcare and life sciences - Cross-border
Q3 2025 in Healthcare and life sciences - Australasia
Q3 2025 in Healthcare and life sciences - Europe
Q2 2025 in Healthcare and life sciences - Australasia
Q2 2025 in Healthcare and life sciences - Europe
Q2 2025 in Healthcare and life sciences - Cross-border
Q1 2025 in Healthcare and life sciences - Australasia
Q1 2025 in Healthcare and life sciences - Europe
Q1 2025 in Healthcare and life sciences - Cross-border
Q4 2024 in Healthcare and life sciences - Australasia
Q4 2024 in Healthcare and life sciences - Europe
Q4 2024 in Healthcare and life sciences - Cross-border
Q3 2024 in Healthcare and life sciences - Australasia
Q3 2024 in Healthcare and life sciences - Europe
Q3 2024 in Healthcare and life sciences - Cross-border
Q2 2024 in Healthcare and life sciences - Australasia
Q2 2024 in Healthcare and life sciences - Cross-border
Q1 2024 in Healthcare and life sciences - Australasia
Q1 2024 in Healthcare and life sciences - Cross-border
Q4 2023 in Healthcare and life sciences - Australasia
Q4 2023 in Healthcare and life sciences - Cross-border
Q3 2023 in Healthcare and life sciences - Australasia
Q3 2023 in Healthcare and life sciences - Cross-border
Q2 2023 in Healthcare and life sciences - Australasia
Q2 2023 in Healthcare and life sciences - Cross-border
Q1 2023 in Healthcare and life sciences - Cross-border
Q3 2022 in IP - Australasia
Q3 2022 in Healthcare and life sciences - Australasia
Q2 2022 in Healthcare and life sciences - Australasia
Q1 2021 in Healthcare and life sciences - Australasia
Q4 2020 in Healthcare and life sciences - Australasia

Less

Offices

Australia

New Zealand

Resources

Daily newsfeed

Panoramic

Research hubs

Learn

In-depth

Lexy Find

Scanner

Contracts & clauses

Lexology Index

Find an expert

Reports

Research methodology

Submissions

FAQ

Instruct Counsel

Client Choice 2025

More

Lexy AI

About us

Legal Influencers

Firms

Blog

Events

Popular

Lexology Academic

Lexology Talent Management

Legal

Terms of use

Cookies

Disclaimer

Privacy policy

Contact

Help centre

Contact

RSS feeds

Submissions

Login

Register

Search Lexology

Q

Follow on X

Follow on LinkedIn

© Copyright 2026 LBR trading as Centellic

CENTELLIC